Overview
Sds Optic is a company that specializes in custom antibody development and small-scale production, offering monoclonal and anti-idiotype antibody services. It also provides advanced optical coatings using nanolayer technology for various industries, including optics, electronics, and medical devices. Additionally, Sds Optic has developed the inPROBE technology, a diagnostic solution that combines photonics with molecular biology to detect HER2 expression for improved cancer treatment access.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 4.00
- High
- PLN 4.22
- Low
- PLN 3.90
- Volume
- 3.17K
- Avg. vol.
- 2K
- Market cap
- PLN 26.70M
- P/E ratio
- —
- EPS
- -PLN 0.39
- Shares outstanding
- 6.68M
- 52-week
- PLN 3.90 – 4.38
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLSDSOP00013
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 175.85k | USD -132.90k | USD -219.07k |
| Q1 2026 | USD 159.64k | USD -121.02k | USD -239.87k |
| Q4 2025 | USD 235.31k | USD -57.51k | USD -80.36k |
| Q3 2025 | USD 222.00k | USD -129.83k | USD -207.94k |
Results for Q3 2026:Nov 10, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2013-07-08. Active
27 1050 1953 1000 0090 3248 1575- 45 1050 1953 1000 0090 3248 1542
- 49 1050 1953 1000 0090 3248 1567
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Aug 23, 2021 | Shareholders' meeting convened |
Public aid
12 public aid cases recorded, with a total value of $2,999,308.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 19, 2024 | Aid for research and development projects: industrial research | $560.1K$560,055 | Marszałek Województwa Lubelskiego | |
| Dec 19, 2024 | Aid for research and development projects: experimental development | $61,698$61,698 | Marszałek Województwa Lubelskiego | |
| Dec 19, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $4,540$4,540 | Marszałek Województwa Lubelskiego |
European Funds
2 projects recorded: 1 from FE lists ($212,482) and 1 Commission grant (FTS) ($4,491,234).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2017-12-01 | 783818 - Sds-omiprobe - revolutionary opto-biological methodology for aggressive her2 cancer | $4.5M$4,491,234 | 1.1.31 - Horizon 2020 | |
| 2017-09-01 | Wsparcie promocji oraz internacjonalizacji urządzenia medycznego służącego do wykrywania substancji aktywnych biologicznie | $212.5K$212,482 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The President of the Management Board acting independently or two members of the management board acting jointly are authorized to make declarations of will concerning the company’s property rights and obligations and to represent the company.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Marcin Czesław Staniszewski (53)  | Prezes zarządu i większościowy udziałowiec sds optonic sp. z o.o. z siedzibą w lublinie będąca akcjonariuszem sds optic s.a. posiadająca ponad 25% udziału w kapitale zakładowym oraz ponad 25% głosów na walnym zgromadzeniu. niestwierdzenie podejrzeń prania pieniędzy lub finansowania terroryzmu. |
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Fibiomedsp. z o.o. | 7,820.10 USD | 82.7143% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Scope FluidicsS.A. | $3,082,936.61 | scopefluidics.com | ||
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| SkinlabP.S.A. | $1,797,229.06 | skinlab.pl | ||
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| Sonovero R&Dsp. z o.o. | $1,231,798.76 | sonovero-rd.pl | ||
| COS LabP.S.A. | $1,028,123.83 | coslab.pl | ||
| Syventosp. z o.o. | $970,435.47 | syvento.com | ||
| Bulletprovesp. z o.o. | $867,545.53 | bulletprove.com | ||
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-03-23 | Share capital change (6,300,450.00 PLN → 6,675,450.00 PLN) | |
| 2025-11-19 | Share capital change (6,125,450.00 PLN → 6,300,450.00 PLN) | |
| 2025-08-07 | Share capital change (5,933,250.00 PLN → 6,125,450.00 PLN) | |
| 2024-07-10 | Share capital change (5,877,550.00 PLN → 5,933,250.00 PLN) | |
| 2023-09-13 | Share capital change (5,830,850.00 PLN → 5,877,550.00 PLN) |
FAQ
Last updated: 2026-07-02